These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21507471)

  • 1. Difference in willingness-to-pay for prostate cancer screening between ill-informed and well-informed men: a contingent valuation survey.
    Yasunaga H; Sugihara T; Imamura T
    Urology; 2011 Jun; 77(6):1325-9. PubMed ID: 21507471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Willingness to pay for mass screening for prostate cancer: a contingent valuation survey.
    Yasunaga H
    Int J Urol; 2008 Jan; 15(1):102-5; discussion 105. PubMed ID: 18184186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit evaluation of mass screening for prostate cancer: willingness-to-pay measurement using contingent valuation.
    Yasunaga H; Ide H; Imamura T; Ohe K
    Urology; 2006 Nov; 68(5):1046-50. PubMed ID: 17113896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Women's anxieties caused by false positives in mammography screening: a contingent valuation survey.
    Yasunaga H; Ide H; Imamura T; Ohe K
    Breast Cancer Res Treat; 2007 Jan; 101(1):59-64. PubMed ID: 16821083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
    van Vugt HA; Roobol MJ; Venderbos LD; Joosten-van Zwanenburg E; Essink-Bot ML; Steyerberg EW; Bangma CH; Korfage IJ
    Eur J Cancer; 2010 Feb; 46(3):669-77. PubMed ID: 20022239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.
    Watson E; Hewitson P; Brett J; Bukach C; Evans R; Edwards A; Elwyn G; Cargill A; Austoker J
    Patient Educ Couns; 2006 Nov; 63(3):367-79. PubMed ID: 16875796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciding on PSA-screening - Quality of current consumer information on the Internet.
    Korfage IJ; van den Bergh RC; Essink-Bot ML
    Eur J Cancer; 2010 Nov; 46(17):3073-81. PubMed ID: 21047589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Educating men about prostate cancer screening. A randomized trial of a mailed pamphlet.
    Wilt TJ; Paul J; Murdoch M; Nelson D; Nugent S; Rubins HB
    Eff Clin Pract; 2001; 4(3):112-20. PubMed ID: 11434074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer screening and informed decision-making: provider and patient perspectives.
    Bowen DJ; Hannon PA; Harris JR; Martin DP
    Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):155-61. PubMed ID: 21243007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for prostate cancer: the current evidence and guidelines controversy.
    Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
    Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of informed consent on patient interest in prostate-specific antigen screening.
    Wolf AM; Nasser JF; Wolf AM; Schorling JB
    Arch Intern Med; 1996 Jun; 156(12):1333-6. PubMed ID: 8651843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of information and private versus public provision on preferences for screening for prostate cancer: a willingness-to-pay study.
    Pedersen LB; Gyrd-Hansen D; Kjær T
    Health Policy; 2011 Aug; 101(3):277-89. PubMed ID: 21680041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial comment.
    Berglund RK
    Urology; 2011 Jun; 77(6):1329; author reply 1329. PubMed ID: 21624593
    [No Abstract]   [Full Text] [Related]  

  • 15. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?
    O'Dell KJ; Volk RJ; Cass AR; Spann SJ
    J Fam Pract; 1999 Sep; 48(9):682-8. PubMed ID: 10498074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Lim LS; Sherin K;
    Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Informed consent for PSA screening: does it happen?
    Federman DG; Goyal S; Kamina A; Peduzzi P; Concato J
    Eff Clin Pract; 1999; 2(4):152-7. PubMed ID: 10539539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men's screening uptake.
    Meiser B; Cowan R; Costello A; Giles GG; Lindeman GJ; Gaff CL
    Urology; 2007 Oct; 70(4):738-42. PubMed ID: 17991547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer screening.
    Sikaris K
    Pathology; 2012 Feb; 44(2):99-109. PubMed ID: 22198258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.